Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B.
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
08
11
2020
revised:
29
11
2020
accepted:
30
11
2020
pubmed:
8
12
2020
medline:
16
3
2022
entrez:
7
12
2020
Statut:
ppublish
Résumé
Persistent serum alanine aminotransferase (ALT) elevation in nucleotide/nucleoside analogue (NA)-treated patients with chronic hepatitis B (CHB) has been associated with unfavorable long-term outcomes.
Identifiants
pubmed: 33285291
pii: S1542-3565(20)31637-2
doi: 10.1016/j.cgh.2020.11.047
pii:
doi:
Substances chimiques
Antiviral Agents
0
Tenofovir
99YXE507IL
Alanine Transaminase
EC 2.6.1.2
tenofovir alafenamide
EL9943AG5J
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
230-232Informations de copyright
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.